Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (2016 - 2025)

United Therapeutics' Shares Outstanding history spans 14 years, with the latest figure at $72.7 million for Q4 2022.

  • For Q4 2022, Shares Outstanding rose 1.39% year-over-year to $72.7 million; the TTM value through Dec 2022 reached $72.7 million, up 1.39%, while the annual FY2022 figure was $72.7 million, 1.39% up from the prior year.
  • Shares Outstanding for Q4 2022 was $72.7 million at United Therapeutics, up from $72.1 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $72.7 million in Q4 2022 and bottomed at $70.1 million in Q1 2018.
  • The 5-year median for Shares Outstanding is $71.0 million (2020), against an average of $71.0 million.
  • The largest annual shift saw Shares Outstanding increased 0.28% in 2020 before it rose 1.39% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $70.2 million in 2018, then grew by 0.43% to $70.5 million in 2019, then rose by 0.85% to $71.1 million in 2020, then increased by 0.84% to $71.7 million in 2021, then grew by 1.39% to $72.7 million in 2022.
  • Per Business Quant, the three most recent readings for UTHR's Shares Outstanding are $72.7 million (Q4 2022), $72.1 million (Q2 2022), and $71.9 million (Q1 2022).